In the past week, CYCC stock has gone up by 0.88%, with a monthly gain of 11.63% and a quarterly plunge of -19.81%. The volatility ratio for the week is 24.06%, and the volatility levels for the last 30 days are 22.04% for Cyclacel Pharmaceuticals Inc The simple moving average for the past 20 days is -2.08% for CYCC’s stock, with a -59.13% simple moving average for the past 200 days.
Is It Worth Investing in Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Right Now?
The stock has a 36-month beta value of 0.47. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CYCC is 21.41M, and at present, short sellers hold a 0.13% of that float. On May 12, 2025, the average trading volume of CYCC was 2.53M shares.
CYCC) stock’s latest price update
The stock of Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) has decreased by -15.53 when compared to last closing price of 0.30.Despite this, the company has seen a gain of 0.88% in its stock price over the last five trading days. globenewswire.com reported 2025-05-07 that BERKELEY HEIGHTS, NJ, May 07, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-16 reverse stock split on its shares of common stock effective May 12, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol “CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L884.
Analysts’ Opinion of CYCC
Many brokerage firms have already submitted their reports for CYCC stocks, with Oppenheimer repeating the rating for CYCC by listing it as a “Outperform.” The predicted price for CYCC in the upcoming period, according to Oppenheimer is $17 based on the research report published on July 18, 2022 of the previous year 2022.
ROTH Capital, on the other hand, stated in their research note that they expect to see CYCC reach a price target of $24. The rating they have provided for CYCC stocks is “Buy” according to the report published on April 27th, 2020.
CYCC Trading at -8.33% from the 50-Day Moving Average
After a stumble in the market that brought CYCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.78% of loss for the given period.
Volatility was left at 22.04%, however, over the last 30 days, the volatility rate increased by 24.06%, as shares surge +14.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.31% lower at present.
During the last 5 trading sessions, CYCC rose by +0.88%, which changed the moving average for the period of 200-days by -84.55% in comparison to the 20-day moving average, which settled at $0.2588. In addition, Cyclacel Pharmaceuticals Inc saw -32.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYCC starting from Lazar David E., who sale 194,628,820 shares at the price of $0.03 back on Feb 26 ’25. After this action, Lazar David E. now owns 0 shares of Cyclacel Pharmaceuticals Inc, valued at $5,507,996 using the latest closing price.
Stock Fundamentals for CYCC
Current profitability levels for the company are sitting at:
- -347.19 for the present operating margin
- 0.91 for the gross margin
The net margin for Cyclacel Pharmaceuticals Inc stands at -215.28. The total capital return value is set at 6.87. Equity return is now at value -807.39, with -173.81 for asset returns.
Currently, EBITDA for the company is -12.0 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 2027.07. The receivables turnover for the company is 0.18for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.59.
Conclusion
To sum up, Cyclacel Pharmaceuticals Inc (CYCC) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
